MedTrace Logo

An Observational Study for Dacogen Long-Term Treatment in Patients With Myelodysplastic Syndrome

NCT01400633 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 156

Last updated 2015-05-25

No results posted yet for this study

Summary

The purpose of this study is to investigate the overall response rate (ORR) and safety when treating patients with myelodysplastic syndrome with decitabine. Decitabine is to be administered as long as there is evidence of clinical benefit.

Conditions

Interventions

DRUG

decitabine injection

decitabine intravenous injection 20mg/m2 once a day for 5 consecutive days every 4 weeks

Sponsors & Collaborators

  • Janssen Korea, Ltd., Korea

    lead INDUSTRY

Principal Investigators

  • Janssen Korea, Ltd. Clinical Trial · Janssen Korea, Ltd.

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-12-31
Primary Completion
2014-03-31
Completion
2014-03-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01400633 on ClinicalTrials.gov